Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Sales | 3,434,300 | 3,362,700 | 3,158,100 | 3,162,100 | 3,414,400 |
| Cost of Goods | 517,000 | 436,400 | 404,900 | 457,500 | 540,600 |
| Gross Profit | 2,917,300 | 2,926,300 | 2,753,200 | 2,704,600 | 2,873,800 |
| Operating Expenses | 1,945,400 | 1,815,700 | 1,737,600 | 1,758,400 | 1,727,600 |
| Operating Income | 972,900 | 1,111,000 | 1,016,500 | 946,700 | 1,146,800 |
| Interest Expense | 18,300 | 17,800 | 18,900 | 18,000 | 17,400 |
| Other Income | 193,000 | 17,600 | 85,300 | -70,700 | 195,300 |
| Pre-tax Income | 1,147,600 | 1,110,800 | 1,082,900 | 858,000 | 1,324,700 |
| Income Tax | -12,000 | 103,000 | 114,500 | 40,200 | 127,600 |
| Net Income Continuous | 1,159,600 | 1,007,800 | 968,400 | 817,800 | 1,197,100 |
| Net Income | $1,159,600 | $1,007,800 | $968,400 | $817,800 | $1,197,100 |
| EPS Basic Total Ops | 10.88 | 9.48 | 9.05 | 7.64 | 11.18 |
| EPS Basic Continuous Ops | 10.89 | 9.48 | 9.05 | 7.64 | 11.19 |
| EPS Diluted Total Ops | 10.21 | 8.89 | 8.50 | 7.17 | 10.48 |
| EPS Diluted Continuous Ops | 10.21 | 8.89 | 8.50 | 7.17 | 10.48 |
| EPS Diluted Before Non-Recurring Items | 10.18 | 10.17 | 8.79 | 8.44 | 10.96 |
| EBITDA(a) | $1,085,899 | $1,216,400 | $1,119,600 | $1,046,200 | $1,246,900 |